High ERK Protein Expression Levels Correlate with Shorter Survival in Triple‐Negative Breast Cancer Patients

The mitogen‐activated protein kinase (MAPK) signaling pathway is known to be activated in triple‐negative breast cancer (TNBC). Extracellular signal–related kinase (ERK), a member of the MAPK pathway, promotes cell proliferation, angiogenesis, cell differentiation, and cell survival. To assess the prognostic impact of ERK in TNBC patients, relative quantities of ERK (ERK‐2 and pMAPK) and direct targets of the ERK pathway (MAPK/ERK kinase 1, phospho‐enriched protein in astrocytes [PEA]‐15, phosphorylated (p)PEA‐15, tuberous sclerosis protein 2, p70S6 kinase, and p27) were measured using reverse‐phase protein arrays in tumor tissue from patients with TNBC (n = 97) and non‐TNBC (n = 223). Protein levels in patients with TNBC were correlated with clinical and tumor characteristics and outcome. The median age of patients with TNBC was 55 years (range, 27–86 years). Disease stage was I in 21%, II in 60%, and III in 20% of the patients. In a multivariate analysis, among patients with TNBC, those with ERK‐2–overexpressing tumors had a lower overall survival rate than those with low ERK‐2–expressing tumors (hazard ratio [HR], 2.76; 95% confidence interval [CI], 1.19–6.41). However, high pMAPK levels were associated with a significantly higher relapse‐free survival rate (HR, 0.66; 95% CI, 0.46–0.95). In conclusion, ERK‐2 and pMAPK are valuable prognostic markers in TNBC. Further studies are justified to elucidate ERK's role in TNBC tumorigenicity and metastasis. The clinical significance of extracellular signal–related kinase (ERK) was assessed in patients with triple‐negative breast cancer versus patients with non–triple negative breast cancer. High ERK‐2 levels were correlated with a lower overall survival rate and high phosphorylated mitogen‐activated protein kinase levels were correlated with a higher relapse‐free survival rate in triple‐negative breast cancer patients.